IRIS
RONCATO, Rossana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.477
AS - Asia 1.647
EU - Europa 782
SA - Sud America 272
AF - Africa 55
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.237
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.411
SG - Singapore 799
CN - Cina 340
BR - Brasile 216
HK - Hong Kong 183
IT - Italia 183
VN - Vietnam 103
DE - Germania 100
RU - Federazione Russa 96
FR - Francia 90
GB - Regno Unito 56
IN - India 56
IE - Irlanda 48
FI - Finlandia 46
KR - Corea 39
CA - Canada 35
BD - Bangladesh 28
NL - Olanda 28
MX - Messico 23
UA - Ucraina 22
AR - Argentina 20
AT - Austria 20
TR - Turchia 17
CH - Svizzera 16
ES - Italia 16
TG - Togo 15
PL - Polonia 14
SE - Svezia 14
CZ - Repubblica Ceca 12
JP - Giappone 12
ID - Indonesia 9
PK - Pakistan 9
ZA - Sudafrica 9
CO - Colombia 8
EC - Ecuador 8
SA - Arabia Saudita 8
IQ - Iraq 7
TN - Tunisia 7
MA - Marocco 6
AE - Emirati Arabi Uniti 5
EG - Egitto 5
VE - Venezuela 5
KE - Kenya 4
LT - Lituania 4
PE - Perù 4
AU - Australia 3
BE - Belgio 3
BO - Bolivia 3
CL - Cile 3
DZ - Algeria 3
JO - Giordania 3
NI - Nicaragua 3
OM - Oman 3
RO - Romania 3
UY - Uruguay 3
AO - Angola 2
AZ - Azerbaigian 2
CR - Costa Rica 2
CY - Cipro 2
DK - Danimarca 2
GE - Georgia 2
KZ - Kazakistan 2
NP - Nepal 2
PH - Filippine 2
PY - Paraguay 2
QA - Qatar 2
TH - Thailandia 2
UZ - Uzbekistan 2
AL - Albania 1
AM - Armenia 1
BG - Bulgaria 1
BH - Bahrain 1
CI - Costa d'Avorio 1
DM - Dominica 1
GR - Grecia 1
GT - Guatemala 1
HR - Croazia 1
IL - Israele 1
IR - Iran 1
JM - Giamaica 1
MT - Malta 1
MY - Malesia 1
MZ - Mozambico 1
NG - Nigeria 1
NO - Norvegia 1
PS - Palestinian Territory 1
PT - Portogallo 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SX - ???statistics.table.value.countryCode.SX??? 1
SY - Repubblica araba siriana 1
TW - Taiwan 1
Totale 5.237
Salva come PNG Salva come JPEG
Città #
Singapore 334
Ashburn 287
San Jose 195
Hong Kong 181
Council Bluffs 170
Beijing 134
Los Angeles 130
Chicago 126
Boardman 110
Fairfield 69
Chandler 68
Salt Lake City 57
Lauterbourg 56
Dallas 53
Dublin 47
Houston 44
Hefei 40
Munich 40
New York 40
Santa Clara 39
Seoul 39
Wilmington 39
Woodbridge 38
Cambridge 32
Elk Grove Village 30
Ho Chi Minh City 30
Seattle 30
Hanoi 28
Buffalo 26
Frankfurt am Main 24
Redondo Beach 24
Tampa 23
Helsinki 22
The Dalles 22
São Paulo 20
Montreal 19
London 17
Nuremberg 17
Zurich 16
Lomé 15
Ann Arbor 14
Genoa 14
Miami 14
Orem 14
Dearborn 13
Denver 13
Pune 13
Turku 13
Vienna 13
Milan 12
Ogden 12
Warsaw 12
Amsterdam 11
Tokyo 11
Brno 10
Chennai 10
Phoenix 10
Rome 10
Stockholm 10
Princeton 9
Sterling 9
Arezzo 8
Brooklyn 8
Dulles 8
Hyderabad 8
Lappeenranta 8
Redmond 8
Mumbai 7
Poplar 7
Udine 7
Ankara 6
Detroit 6
Guangzhou 6
Jacksonville 6
Lancaster 6
Manchester 6
Mexico City 6
Portsmouth 6
Shanghai 6
Shenzhen 6
Belluno 5
Belo Horizonte 5
Des Moines 5
Düsseldorf 5
Guarulhos 5
Guayaquil 5
Haiphong 5
Madrid 5
Naples 5
New Delhi 5
Rio de Janeiro 5
Toronto 5
Tunis 5
Atlanta 4
Boston 4
Brasília 4
Cormons 4
Da Nang 4
Deiva Marina 4
Hải Dương 4
Totale 3.200
Salva come PNG Salva come JPEG
Nome #
Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment 551
Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC) 185
A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer 146
Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity 145
The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines 129
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure 123
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer? 121
DPYD gene activity score (GAS) predicts dose-limiting toxicity in fluoropyrimidine-treated colorectal cancer patients 120
Abstract PD10-01: Impact of ESR1 mutations on Selective Estrogen Receptor Degraders and Modulators: an integrated liquid-biopsy and pharmacodynamics approach 118
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer 112
SMAD3 Host and Tumor Profiling to Identify Locally Advanced Rectal Cancer Patients at High Risk of Poor Response to Neoadjuvant Chemoradiotherapy 112
Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk 106
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer 104
CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patients 102
The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice 101
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study 100
JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future 98
FARMAPRICE: A Pharmacogenetic Clinical decision support system for precise and Cost-Effective Therapy 97
IL15RA and SMAD3 Genetic Variants Predict Overall Survival in Metastatic Colorectal Cancer Patients Treated with FOLFIRI Therapy: A New Paradigm 93
NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome 93
Correction: Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy (Cell Death & Disease, (2022), 13, 4, (398), 10.1038/s41419-022-04741-9) 88
Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy 85
Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis 82
Clinical Benefits and Utility of Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer 80
Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method 80
Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer 79
The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity 79
LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring 76
The challenge of molecular selection in liver-limited metastatic colorectal cancer for surgical resection: a systematic review and meta-analysis in the context of current and future approaches 75
mHealth Apps Available in Italy to Support Health Care Professionals in Antimicrobial Stewardship Implementation: Systematic Search in App Stores and Content Analysis 75
Implementation of preemptive testing of a pharmacogenomic panel in clinical practice: Where do we stand? 73
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions 73
Inositol and Non-Alcoholic Fatty Liver Disease: A Systematic Review on Deficiencies and Supplementation 73
Body mass index impacts adverse events and drug plasma concentration: should dose intensity be included in the palbociclib equation? 72
Lipid rafts as viral entry routes and immune platforms: A double-edged sword in SARS-CoV-2 infection? 70
A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients 69
Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy 68
The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure 67
Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype 67
New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach 66
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways 66
Cancer Pharmacogenetics: perspective on newly discovered and implemented predictive biomarkers 66
Therapeutic drug monitoring for the cancer patient: challenges and opportunities 65
Quantification of Letrozole, Palbociclib, Ribociclib, Abemaciclib, and Metabolites in Volumetric Dried Blood Spots: Development and Validation of an LC-MS/MS Method for Therapeutic Drug Monitoring 65
Genetic biomarkers for hepatocellular cancer risk in a caucasian population 65
Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS) 64
European association for clinical pharmacology and therapeutics young clinical pharmacologists working group: a cornerstone for the brighter future of clinical pharmacology 62
Pharmacovigilance, drug interactions, pharmacogenetics and therapeutic drug monitoring of anticancer agents: a valuable support for clinical practice 62
Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines 61
Clinical relevance and methodological approach for the assessment of drug–drug interactions in cancer patients: a position statement from the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pharmacology (SIF) 59
Cost-utility analysis and cross-country comparison of pharmacogenomics-guided treatment in colorectal cancer patients participating in the U-PGx PREPARE study 59
Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma 58
Ubiquitous Pharmacogenomics (U-PGx): The Time for Implementation is Now. An Horizon2020 Program to Drive Pharmacogenomics into Clinical Practice 58
Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine 52
Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation 50
Improving decision making on DPYD and UGT1A1*28 patients' profiling with an innovative reimbursement strategy 50
Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI 45
Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients 43
Exploring pharmacokinetic variability of palbociclib in HR+/HER2- metastatic breast cancer: a focus on age, renal function, and drug–gene interactions 39
Uptake of DPYD and UGT1A1 testing in Italy and adherence to pharmacogenetic guidelines: A 5-year perspective from an EQA provider 34
Integration of germline pharmacogenomic burden to predict fluoropyrimidine-related toxicity – A secondary analysis of the PREPARE trial 24
Pharmacokinetics of therapies approved for spinal muscular atrophy: A narrative review of current evidence 15
Pharmacogenetic testing in Italy: results of a nationwide survey by the Joint Working Group for the pharmacogenetics implementation in Italy 12
Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape 9
Editorial: Innovations in pharmacogenomics: embracing diversity and clinical application 9
DPYD and UGT1A1 Genotype‐Based Dosing for Fluoropyrimidines and Irinotecan Chemotherapy: Variant‐Specific Impact on Treatment Intensity and Toxicity 7
Pharmacogenetic Implementation Studies—Lessons Learned From the PREPARE Study 3
A systematic literature review of economic evaluations of setmelanotide 3
Multinational cost-utility analysis of panel-based pharmacogenetics-guided treatment of patients enrolled in the U-PGx PREPARE study 3
Totale 5.461
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.326
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.326
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215 0 0 0 0 0 0 0 0 0 0 0 5
2021/202266 3 5 0 4 2 2 11 0 4 10 14 11
2022/2023318 9 3 4 77 59 70 0 22 45 4 9 16
2023/2024339 31 19 11 4 39 40 21 15 19 31 25 84
2024/20251.233 53 87 42 37 85 69 91 57 126 99 221 266
2025/20263.148 456 408 403 223 320 206 307 95 164 214 243 109
Totale 5.461